Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons.
Neurturin (NTN) and glial cell line-derived neurotrophic factor (GDNF), two members of the GDNF family of growth factors, exert very similar biological activities in different systems, including the substantia nigra. Our goal in the present work was to compare their function and define whether nonoverlapping biological activities on midbrain dopaminergic neurons exist. We first found that NTN and GDNF are differentially regulated during postnatal development. NTN mRNA progressively decreased in the ventral mesencephalon and progressively increased in the striatum, coincident with a decrease in GDNF mRNA expression. This finding suggested distinct physiological roles for each factor in the nigrostriatal system. We therefore examined their function in ventral mesencephalon cultures and found that NTN promoted survival comparable with GDNF, but only GDNF induced sprouting and hypertrophy of developing dopaminergic neurons. We subsequently examined the ability of NTN to prevent the 6-hydroxydopamine-induced degeneration of adult dopaminergic neurons in vivo. Fibroblasts genetically engineered to deliver high levels of GDNF or NTN were grafted supranigrally. NTN was found to be as potent as GDNF at preventing the death of nigral dopaminergic neurons, but only GDNF induced tyrosine hydroxylase staining, sprouting, or hypertrophy of dopaminergic neurons. In conclusion, our results show selective survival-promoting effects of NTN over wider survival, neuritogenic, and hypertrophic effects of GDNF on dopaminergic neurons in vitro and in vivo. Such differences are likely to underlie unique roles for each factor in postnatal development and may ultimately be exploited in the treatment of Parkinson's disease.
Akerud
P
P
Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Alberch
J
J
Eketjäll
S
S
Wagner
J
J
Arenas
E
E
D000818:Animals; D002455:Cell Division; D004298:Dopamine / Q000502:physiology*; D005347:Fibroblasts / Q000378:metabolism / Q000637:transplantation; D018507:Gene Expression Regulation, Developmental; D005818:Genetic Engineering; D051100:Glial Cell Line-Derived Neurotrophic Factor; D008297:Male; D051379:Mice; D009410:Nerve Degeneration / Q000517:prevention & control; D009414:Nerve Growth Factors / Q000235:genetics / Q000494:pharmacology*; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000494:pharmacology*; D016501:Neurites / Q000502:physiology; D009457:Neuroglia / Q000378:metabolism*; D009474:Neurons / Q000166:cytology* / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology; D051101:Neurturin; D016627:Oxidopamine / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344; D013378:Substantia Nigra / Q000166:cytology / Q000254:growth & development* / Q000378:metabolism
C495040:Gdnf protein, mouse; C495041:Gdnf protein, rat; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D051101:Neurturin; C495056:Nrtn protein, mouse; C495057:Nrtn protein, rat; D012333:RNA, Messenger; D016627:Oxidopamine; D004298:Dopamine